» Articles » PMID: 17261655

Detection of Coronary Microembolization by Doppler Ultrasound in Patients with Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Interventions

Overview
Journal Circulation
Date 2007 Jan 31
PMID 17261655
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Intracoronary Doppler guidewires can be used for real-time detection and quantification of microembolism during percutaneous coronary interventions (PCIs). We investigated whether the frequency of Doppler-detected microembolism is related to the incidence of myonecrosis during elective PCI.

Methods And Results: The study population included 52 consecutive patients (aged 64+/-10 years; 36 men, 16 women) with coronary artery disease who underwent elective PCI of a single-vessel stenosis. Using intracoronary Doppler ultrasound, we compared the frequency of microembolism during PCI in 22 patients with periprocedural non-ST-segment elevation myocardial infarctions (pNSTEMI) and 30 patients without pNSTEMI. The 2 groups were comparable with regard to their clinical and procedural characteristics. In the group with pNSTEMI, the total number of coronary microemboli after PCI (27+/-10 versus 16+/-8, P<0.001) was higher than in the group without pNSTEMI. Although high-sensitivity C-reactive protein plasma levels were similar before PCI (2.9+/-2.2 versus 3.4+/-1.7 mg/L, P=NS), they were higher in the group with pNSTEMI after PCI (12.6+/-10.4 versus 6.1+/-5.1 mg/L, P<0.05). Microembolic count independently correlated to postprocedural cardiac troponin I elevation (r=0.565, P<0.001), coronary flow velocity reserve (r=-0.506, P<0.001), and baseline average peak velocity (r=0.499, P<0.001).

Conclusions: Patients with pNSTEMI had a significantly higher frequency of coronary microembolization during PCI, and their systemic inflammatory response and microvascular impairment after PCI were more pronounced. Intracoronary Doppler ultrasound provides evidence that pNSTEMI in patients undergoing elective PCI is caused by microembolization during the procedure.

Citing Articles

Periprocedural Myocardial Infarction following Elective Percutaneous Coronary Interventions.

Landi A, Montalto C, Crimi G, De Servi S Rev Cardiovasc Med. 2024; 23(9):309.

PMID: 39077696 PMC: 11262399. DOI: 10.31083/j.rcm2309309.


Resveratrol pretreatment alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis by targeting TLR4/MyD88/NF-κB signaling cascade in coronary microembolization-induced myocardial damage.

Luo C, Li T, Li H, Zhou Y, Li L Korean J Physiol Pharmacol. 2023; 27(2):143-155.

PMID: 36815254 PMC: 9968948. DOI: 10.4196/kjpp.2023.27.2.143.


Tanshinone IIA reduces pyroptosis in rats with coronary microembolization by inhibiting the TLR4/MyD88/NF-κB/NLRP3 pathway.

Li H, Li T, Chen Z, Li L Korean J Physiol Pharmacol. 2022; 26(5):335-345.

PMID: 36039734 PMC: 9437365. DOI: 10.4196/kjpp.2022.26.5.335.


A fresh look at coronary microembolization.

Kleinbongard P, Heusch G Nat Rev Cardiol. 2021; 19(4):265-280.

PMID: 34785770 PMC: 8593642. DOI: 10.1038/s41569-021-00632-2.


miR-200a-3p Attenuates Coronary Microembolization-Induced Myocardial Injury in Rats by Inhibiting TXNIP/NLRP3-Mediated Cardiomyocyte Pyroptosis.

Chen Z, Zhou Y, Chen F, Huang J, Li H, Li T Front Cardiovasc Med. 2021; 8:693257.

PMID: 34422922 PMC: 8374895. DOI: 10.3389/fcvm.2021.693257.